Total study population N = 780 | Too well to benefit—No ICU N = 258 | Too well to benefit—Delayed ICU N = 74 | ICU N = 382 | Too sick to benefit N = 66 | p-value | |
---|---|---|---|---|---|---|
Age | 64 [56–70] | 63 [54–69] | 66 [59–70] | 65 [58–72] | 63 [56–70] | 0.04* |
Male | 499 (64%) | 166 (64.3%) | 44 (59.5%) | 248 (64.9%) | 41 (62.1%) | 0.82 |
Solid malignancy | 503 (64.7%) | 163 (63.2%) | 41 (55.4%) | 244 (63.9%) | 55 (83.3%) | 0.005* |
Hematological malignancy | 274 (35.3%) | 94 (36.4%) | 33 (44.6%) | 136 (35.6%) | 11 (16.7%) | |
Both | 3 (0.4%) | 1 (0.4%) | 2 ( 0.5%) | |||
Metastatic solid malignancy | 245 (31.4%) | 75 (29.1%) | 20 (27%) | 108 (28.3%) | 42 (63.6%) | < 0.001* |
Cancer recurrence | 71 (9.1%) | 33 (12.8%) | 5 (6.8%) | 27 (7.1%) | 6 (9.1%) | 0.09 |
Uncontrolled cancer | 408 (52.4%) | 145 (56.2%) | 33 (44.6%) | 173 (45.4%) | 57 (86.4%) | < 0.001* |
CCI | 4 [2–6] | 4 [2–6] | 3 [2–6] | 4 [2–6] | 6 [4–7] | < 0.001* |
ECOG PS before hospital | 1 [1–2] | 1 [1–2] | 1 [1–1] | 1 [0–2] | 2 [1–3] | < 0.001* |
0 | 181 (23.2%) | 54 (20.9%) | 17 (23%) | 108 (28.3%) | 2 (3%) | |
1 | 298 (38.2%) | 93 (36%) | 39 (52.7%) | 148 (38.7%) | 18 (27.3%) | |
2 | 191 (24.5%) | 74 (28.7%) | 15 (20.3%) | 81 (21.2%) | 21 (31.8%) | |
3 | 90 (11.5%) | 31 (12%) | 3 (4.1%) | 36 (9.4%) | 20 (30.3%) | |
4 | 15 (1.9%) | 5 (1.9%) | 0 (0%) | 6 (1.6%) | 4 (6.1%) | |
Unknown | 5 (0.6%) | 1 (0.4%) | 0 (0%) | 3 (0.8%) | 1 (1.5%) | |
MEWS | 5 [3–6] | 4 [2–6] | 5 [4–7] | 5 [4–7] | 5 [3–6] | < 0.001* |
Unknown | 80 (10.3%) | 14.(5.4%) | 4 (5.4%) | 54 (14.1%) | 8 (12.1%) | |
Cancer treatment before ICU | 684 (88%) | 223 (86.8%) | 65 (87.8%) | 343 (90.3%) | 53 (80.3%) | 0.12 |
Unknown | 3 (0.4%) | |||||
Immunocompromised | 560 (71.8%) | 199 (77.1%) | 49 (66.2%) | 265 (69.4%) | 47 (71.2%) | 0.13 |
Year ICU consult | 0.20 | |||||
2016 | 214 (27.4%) | 67 (26%) | 22 (29.7%) | 114 (29.8%) | 11 (16.7%) | |
2017 | 204 (26.2%) | 62 (24%) | 18 (24.3%) | 108 (28.3%) | 16 (24.2%) | |
2018 | 222 (28.5%) | 78 (30.2%) | 18 (24.3%) | 99 (25.9%) | 27 (40.9%) | |
2019 | 140 (17.9%) | 51 (19.8%) | 16 (21.6%) | 61 (16%) | 12 (18.2%) | |
Earlier ICU admission before consult | 77 (9.9%) | 24 (9.3%) | 8 (10.8%) | 45 (11.8%) | 0 (0%) | 0.03* |
One ICU physician | 318 (40.8%) | 109 (42.2%) | 35 (47.3%) | 158 (41.4%) | 16 (24.2%) | 0.007* |
Two ICU physicians | 385 (49.4%) | 130 (50.4%) | 37 (50%) | 176 (46.1%) | 42 (63.6%) | |
More than two ICU physicians | 77 (9.9%) | 19 (7.4%) | 2 (2.7%) | 48 (12.6%) | 8 (12.1%) | |
One referring physician (ref) | 164 (21.2%) | 59 (23%) | 19 (26%) | 80 (21.2%) | 6 (9.1%) | < 0.001* |
Two referring physicians | 496 (64.2%) | 175 (68.1%) | 41 (56.2%) | 240 (63.7%) | 40 (60.6%) | |
More than two referring physicians | 113 (14.6%) | 23 (8.9%) | 13 (17.8%) | 57 (15.1%) | 20 (30.3%) | |
Location consult | < 0.001* | |||||
Emergency room (ref) | 137 (17.6%) | 30 (11.6%) | 4 (5.4%) | 81 (21.2%) | 22 (33.3%) | |
Ward | 483 (61.9%) | 197 (76.4%) | 55 (74.3%) | 190 (49.7%) | 41 (62.1%) | |
Other | 160 (20.5%) | 31 (12%) | 15 (20.3%) | 111 (29.1%) | 3 (4.5%) | |
On-hours (ref) | 315 (40.4%) | 95 (36.8%) | 27 (36.5%) | 163 (42.7%) | 30 (45.5%) | 0.34 |
Off-hours | 465(59.6%) | 163 (63.2%) | 47 (63.5%) | 219 (57.3%) | 36 (54.5%) | |
Weekend | 244 (31.3%) | 77 (29.8%) | 25 (33.8%) | 118 (30.9%) | 24 (36.4%) | 0.73 |
Consult reason | ||||||
Shock | 150 (19.2%) | 30 (11.6%) | 5 (6.8%) | 103 (27%) | 12 (18.2%) | < 0.001* |
Respiratory insufficiency | 483 (61.9%) | 147 (57%) | 50 (67.6%) | 242 (63.4%) | 44 (66.7%) | 0.20 |
Altered consciousness | 139 (17.8%) | 36 (14.0%) | 7 (9.5%) | 80 (20.9%) | 16 (24.2%) | 0.01* |
Sepsis | 214 (27.4%) | 47 (18.2%) | 22 (29.7%) | 135 (35.3%) | 10 (15.2%) | < 0.001* |
Acute kidney injury | 94 (12.1%) | 18 (7%) | 10 (13.5%) | 60 (15.7%) | 6 (9.1%) | 0.008* |
High MEWS | 23 (2.9%) | 16 (6.2%) | 3 (4.1%) | 2 (0.5%) | 2 (3%) | 0.001* |
Hemodynamic instability | 280 (35.9%) | 86 (33.3%) | 21 (28.4%) | 152 (39.8%) | 21 (31.8%) | 0.14 |
Other | 99 (12.7%) | 42 (16.3%) | 9 (12.2%) | 36 (9.4%) | 12 (18.2%) | 0.05 |